To a layperson, the abstract (in the link you posted) has similar lingo as in the RVX NR of March 23, 2020. (as in the below)
"In a recent New York Times article published on March 17th, 2020, researchers at the Quantitative Biosciences Institute Coronavirus Research Group, University of California, San Francisco, identified the human bromodomain-containing protein (BRD2) – a direct target of apabetalone – as a critical interaction partner for SARS-CoV-2. Publications are pending. BRD2 binds to the E (envelope) protein of the virus particles and is believed to participate in the viral reproduction process. Furthermore, apabetalone is known to inhibit expression of Angiotensin-converting enzyme 2 (ACE2), the receptor utilized by the novel coronavirus particles to gain entry into human cells. Together, these observations suggest apabetalone treatment may potentially reduce viral entry into cells, and limit virus particles’ ability to replicate."
Koo
